Mr. Yoav Raiter reports

RELAY MEDICAL REPORTS GLOW LIFETECH SECURES EXCLUSIVE NORTH AMERICAN RIGHTS TO ARTEMIC FOLLOWING SUCCESSFUL COVID-19 PHASE II CLINICAL TRIAL

Glow LifeTech Ltd., a private company in which Relay Medical Corp. holds a significant equity interest, has executed an agreement with Swiss Pharmacan AG for exclusive North American and Caribbean sales and distribution rights for ArtemiC, a natural health product based on Glow's MyCell technology, which recently reported successful results from a COVID-19 phase 2 clinical trial (see Relay's release dated Jan. 14, 2021).

Under the terms of the agreement, signed on Feb. 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, the United States, Mexico and all Carribean countries as a food supplement. ArtemiC is a clinically tested food supplement (nutraceutical, dietary supplement and natural health product) containing four natural-based ingredients consisting of artemisinin, curcumin, boswellia serrata and vitamin C. The formulation uses Glow's MyCell delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC was a collaborative development effort with Glow's strategic partner, Swiss PharmaCan AG and MGC Pharma, and will be manufactured by MGC Pharma under European Union good manufacturing practices.

"This is a significant new product opportunity for Glow and our shareholders as ArtemiC shows promising results that it may improve the clinical recovery of COVID-19 patients," said Rob Carducci, chief commercial officer, Glow LifeTech. "We are extremely pleased that our MyCell technology is helping to power a natural, safe and effective product that can be made widely accessible during these challenging times."

Recently, MGC announced the results of a phase 2 double-blind, placebo-controlled clinical trial, which showed ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the placebo group. One hundred per cent of the patients in the treatment group met the trial's primary end point and fully recovered within 15 days. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared with 23.4 per cent in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing done by MGC on toxicity and mechanism of action.

"We continue to be encouraged with the broad applications of MyCell delivery technology and Glow's commitment to bring scientifically validated products to market," said Yoav Raiter, chief executive officer, Relay. "We believe ArtemiC is just the first of many innovative products to come from Glow, and as such, Relay has committed to participating in their recent [reverse takeover] financing."

On Feb. 9, 2021, Relay announced its participation in the go-public financing of Glow, investing an additional $600,000 to minimize dilution of its equity position. The Glow go-public financing was oversubscribed for a total of $4.64-million, which is part of its conditional approval to list its common shares on the Canadian Securities Exchange.

Glow and Swiss PharmaCan are now preparing regulatory submissions to pave the way for North American commercialization as a food supplement, or equivalent, in each of the relevant jurisdictions.

About Relay Medical Corp.

Relay is a technology developer and innovator, headquartered in Toronto, Canada, focused on the development of novel technologies in the diagnostics and artificial intelligence data science sectors.

We seek Safe Harbor.